Semaglutide – Levers.Health
US$ 27.73
glp 1 based therapy for diabetes UC Davis Health examines systemic impact of GLP-1–based therapies American drugmakers pushed GLP1 therapies
Description
In the SURMOUNT-1 trial, participants following this dosing protocol achieved mean weight reductions of 15.0% (5 mg dose), 19.5% (10 mg dose), and 20.9% (15 mg dose) at 72 weeks, compared to 3.1% with placebo
10.1007/BF02064202 74 LeechC
Week-by-week weight loss should still be relatively minor, and you may not see any physical changes just yet, but dont be disheartened
Many telehealth platforms and weight loss clinics now prescribe compounded semaglutide
Delhanty P, van der Lely A-J
(2021, October 18)
